According to an article posted on DrugResearcher.com , China was chosen both for cheap labor and facilities, as well as a huge urban patient pool.
A trial in China could cost half of what it does in the U.S., says the report. With clinical trials accounting for up to two-thirds of the cost of drug development, savings could be substantial.
Five areas evaluated included patient availability, cost-efficiency, expertise, regulatory conditions and infrastructure. India, Russia, Brazil and the Czech Republic followed behind China.
A trial in China could cost half of what it does in the U.S., says the report. With clinical trials accounting for up to two-thirds of the cost of drug development, savings could be substantial.
Five areas evaluated included patient availability, cost-efficiency, expertise, regulatory conditions and infrastructure. India, Russia, Brazil and the Czech Republic followed behind China.